Hospital Xiamen Humanity
| China | Turquia | Áustria | |
| Tratamento complexo do sarcoma de Ewing | de $75,000 | de $30,000 | de $55,000 |
| Tratamento complexo do neuroblastoma | de $145,000 | de $28,000 | de $180,000 |
| Transplante de medula óssea | de $55,000 | de $36,000 | de $140,000 |
| Transplante autólogo de medula óssea | de $52,000 | de $31,500 | de $50,000 |
| Transplante alogénico de medula óssea de dador relacionado | de $78,000 | de $65,000 | de $150,000 |
A Bookimed não adiciona taxas extras aos preços de tratamento de Oncologia Pediátrica. As tarifas vêm das listas oficiais das clínicas. O pagamento é feito diretamente na clínica na chegada ao país.
A Bookimed está comprometida com sua segurança. Trabalha apenas com instituições que mantêm altos padrões internacionais no tratamento de Oncologia Pediátrica e têm as licenças necessárias para atender pacientes internacionais em todo o mundo.
A Bookimed oferece assistência gratuita de especialistas. Um coordenador médico pessoal apoia antes, durante e após o tratamento, solucionando problemas. Nunca está sozinho em sua jornada de tratamento de Oncologia Pediátrica.
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
Pediatric oncology survival rates in leading Chinese centers now reach 77.2% overall. Top facilities in Beijing and Shanghai report 90% survival for acute lymphoblastic leukemia. This matches international standards. These outcomes stem from standardized protocols and rapid treatment starts within days of diagnosis.
Bookimed Expert Insight: Data from Yanda International Hospital shows that Class A Level III clinics often blend international protocols with traditional approaches. This combination frequently accommodates over 2,500,000 patients annually. High patient volumes in these top-tier Beijing facilities allow surgeons to gain more practical experience in months than many Western specialists see in years.
Patient Consensus: Parents often choose top Chinese centers because treatment starts almost immediately compared to long Western wait times. While families worry about language barriers, they value hitting 95% cure rates for low-risk cases at specialized oncology units.
Pediatric oncologists at top Chinese centers hold National Health Commission (NHC) certifications and advanced academic titles like Chief Physician. Leading institutions like Fuda Cancer Hospital and Yanda International Hospital maintain Joint Commission International (JCI) accreditation. This ensures adherence to rigorous global safety and treatment standards.
Bookimed Expert Insight: Data from Yanda International Hospital and Fuda Cancer Hospital indicates a trend toward high-volume specialization. Yanda serves 2,500,000 patients annually and holds Class A Level III status. This volume allows clinicians to gain experience in rare pediatric cases faster than in smaller regional centers.
Patient Consensus: Families often suggest requesting a written credential summary in English before beginning treatment. They note that institutional JCI accreditation is a reliable indicator of quality when individual physician records are hard to verify.
Pediatric oncology centers in China calculate chemotherapy doses using body surface area or weight-based formulas. Methods vary by age, size, and physiological maturity to ensure precision. Doctors at facilities like Fuda Cancer Hospital use these metrics alongside intensive supportive care to minimize systemic toxicity during treatment.
Bookimed Expert Insight: Leading Chinese oncology hospitals often combine international protocols with unique protective strategies. For example, some centers cap cumulative anthracycline doses at 300mg/m² to prioritize long-term heart health. This conservative approach provides a higher safety margin compared to some Western standards. Choosing a Class A Level III clinic ensures access to these rigorous monitoring technologies and specialized pediatric safety protocols.
Patient Consensus: Parents emphasize the importance of tracking daily side effects in a log for the medical team. Collective experiences suggest joining local support groups helps navigate hospital-specific tips and managing the emotional reality of treatment.
Children can receive both therapies during one multi-week medical stay. China offers rapid access to proton-beam treatment. However, biological timelines define the process. CAR-T cell manufacturing requires at least 10 days. Proton planning takes several days after the initial simulation scan.
Bookimed Expert Insight: Clinical data shows Chinese centers like Yanda International and Xiamen Humanity manage massive patient volumes. This high throughput often results in more efficient diagnostic pipelines. While CAR-T manufacturing is a fixed biological wait, these hospitals use integrated clinical departments to run proton simulations simultaneously. This overlaps the waiting periods and reduces the total stay by several days.
Patient Consensus: Parents note that starting the approval process via remote hospital groups can cut in-person waiting times. They emphasize that while proton therapy starts quickly, the 10-day lab phase for CAR-T cells is unavoidable.
Pediatric oncology centers in China use next-generation sequencing, PCR analysis, and FISH testing to identify actionable mutations. These genomic profiles help doctors select targeted therapies like larotrectinib for specific gene fusions. Standard molecular results typically take 1 to 3 weeks depending on panel complexity.
Bookimed Expert Insight: Chronic disease centers like Xiamen Humanity Hospital manage nearly 1,000,000 patients annually. Their high volume often supports on-site clinical trial capabilities for new cancer drugs. Patients at such large-scale facilities may gain faster access to advanced IVD diagnostic products compared to smaller regional centers.
Patient Consensus: Families often find that major city hospitals deliver results much faster than labs abroad. Some note that ensuring a high-quality tissue sample is the most critical step for successful molecular profiling.
Pediatric oncology treatment in China typically requires 2 to 6 weeks of inpatient care. Autologous transplants usually involve 2 to 3 weeks of hospitalization. Allogeneic procedures often extend stays to 4 or 6 weeks. Full recovery for children takes 3 to 18 months depending on the transplant type.
Bookimed Expert Insight: Chinese tertiary hospitals like Yanda International and Xiamen Humanity Hospital manage massive patient volumes, often exceeding 1,000,000 annually. This high frequency allows clinicians to streamline discharge protocols. Some centers use outpatient NK cell infusions to shorten inpatient stays to 4 weeks, significantly faster than many Western protocols.
Patient Consensus: Parents suggest budgeting 6 to 10 weeks for the inpatient phase and emphasize staying close to the clinic for daily bloodwork. They note that while initial discharge may happen quickly, keeping a strict stock of masks and antivirals is essential for home recovery.
International families prefer Beijing and Guangzhou for pediatric oncology due to advanced treatment infrastructure. Beijing hosts Class A Level III centers like Yanda International Hospital, which is JCI-accredited. Guangzhou's Fuda Cancer Hospital attracts patients from 100+ countries with specialized minimally invasive therapies for advanced cases.
Bookimed Expert Insight: A clear pattern emerges where high-volume centers leverage massive scale to refine specialized care. Yanda International Hospital performs 9,000 operations annually, while Xiamen Humanity Hospital manages 1,000,000 patients. This immense procedural volume often leads to highly efficient diagnostic timelines for international families.
Patient Consensus: Parents often choose Beijing because international departments handle essential visas very quickly. They note that choosing JCI-accredited facilities in major cities helps avoid common language barriers and ensures better follow-up care.